Global levels of histone modifications predict prostate cancer recurrence.
about
One-Carbon Metabolism in Prostate Cancer: The Role of Androgen SignalingHistone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and preventionEpigenetics meets radiation biology as a new approach in cancer treatmentEpigenetic modulators as therapeutic targets in prostate cancerHistone demethylase lysine demethylase 5B in development and cancerThe role of epigenetics in resistance to Cisplatin chemotherapy in lung cancerKDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage.Exploiting Epigenetic Alterations in Prostate Cancer.Epigenetic Signature: A New Player as Predictor of Clinically Significant Prostate Cancer (PCa) in Patients on Active Surveillance (AS)Histone H2A.Z deregulation in prostate cancer. Cause or effect?Epigenetics of prostate cancer and the prospect of identification of novel drug targets by RNAi screening of epigenetic enzymes.Epigenetic Signatures in Breast Cancer: Clinical PerspectiveAlterations of global histone H4K20 methylation during prostate carcinogenesis.Histone modifications and chromatin organization in prostate cancerQuantitative research of histone H3 acetylation levels of human hepatocellular carcinoma cells.SUV39H1/H3K9me3 attenuates sulforaphane-induced apoptotic signaling in PC3 prostate cancer cells.Development of a nuclear morphometric signature for prostate cancer risk in negative biopsies.Epigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth.SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination.Epigenetics in prostate cancer.Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update.Role of diet in prostate cancer: the epigenetic link.Epigenetic regulation of prostate cancerProteomic profiling identifies specific histone species associated with leukemic and cancer cellsγ-H2AX and other histone post-translational modifications in the clinic.Histone modifications and cancer: biomarkers of prognosis?microRNA-101 inhibits lung cancer invasion through the regulation of enhancer of zeste homolog 2Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.KAT5 and KAT6B are in positive regulation on cell proliferation of prostate cancer through PI3K-AKT signaling.Endometriosis is characterized by a distinct pattern of histone 3 and histone 4 lysine modifications.Circulating Nucleosomes and Nucleosome Modifications as Biomarkers in CancerPharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy.Targeting oxidative stress in cancer.Epigenetic modifications as therapeutic targets.The path to epigenetic treatment of memory disorders.Hypomethylation of repeated DNA sequences in cancer.Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there.The Interactions of microRNA and Epigenetic Modifications in Prostate Cancer.The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression.Prostate cancer epigenetic biomarkers: next-generation technologies.
P2860
Q26740548-5FA547EC-7B9F-4A82-8D58-E766EE168076Q26994739-00E1535D-4F67-4DBC-8F97-B94BFC8094B1Q27014984-57A7B432-6418-48E6-8968-DC264AB54753Q28071912-BB4B69EE-4E6E-45EE-BB44-5D6DE45309BCQ28076257-47B76198-0D56-451F-A5B8-BA077D572310Q28387891-74EBE39C-8E44-4564-81A4-9F7787EB1CB5Q33580494-4074EE83-E859-46F8-A948-DA87BC59D3CBQ33755160-D5ED67DB-853E-4217-9076-00A559CE5B16Q33838513-23F5E4AF-6471-4D42-B994-E48B51988CE7Q33962848-217BAFB7-320D-40CF-8731-95CC09292BEBQ34084746-8CB02C07-8A97-4026-8920-BA8713DCAC3DQ34095995-0A2B1AAD-B64C-427D-BD9C-8D68639A82A1Q34194181-2DDADC6E-544A-4206-AEF9-A502E9F97C9FQ34559303-A5F36690-3B8B-4F9A-B0BB-730F753330E7Q34581453-5929C8CC-00AC-4CFA-B8AE-90AC0FC605BCQ34766981-A8667982-9B0F-4230-A120-91F20A06F84EQ34902668-21A8D403-60AF-4B16-9848-8982C17D04C8Q35163061-4D9A437E-25D1-47F0-81C8-AB4DC7652CE6Q35176138-21CA7D6E-6268-4B12-B99D-4DC0AF42ECA7Q35608952-BC7C126D-C481-4939-860B-A297F93E240DQ35726371-0BAD26A2-D3D8-4BC2-8C24-E28CE8ECF35DQ35768176-64CF1DF3-A0CB-4745-BEC3-530A7E7539C3Q36001910-4D8E544B-A3D3-47FE-BBA6-0203889D4134Q36001960-68B59D49-5CF6-4181-A2FB-ECA29CC60A7EQ36019818-9DA8A951-536D-4A10-A402-E684D84F1851Q36206499-A91A40D3-5B5B-476C-8416-B438FA28EFF4Q36230699-CF6BCCAE-1E5C-4254-8EEF-AA5985CFB521Q36515134-BFC1C147-D76F-4A24-95D0-D266FBAAE375Q37349488-A7CB0124-649D-420A-B6D8-8B5ED959AE26Q37606205-11B6A13A-FAF1-4458-B8FD-0F4C4460B997Q37629542-98AB714A-4F61-476B-A3E5-D60559785988Q37730440-48E8E4F5-ED53-45B8-8D2E-7A1AF44E6523Q37799839-D2FBD474-A533-4BCF-A812-7FF3861649DCQ37800011-48DAFFFC-4E44-48A7-B963-23C744B24F4CQ37841833-BE98780A-BAE7-467F-8A57-7D07A2431210Q37961724-0F404098-E8D2-49EA-8B85-42676AFCE9BEQ38002825-ED720EC5-1619-4C59-B992-21CFBE077E6FQ38160734-E2EC7D68-6C0A-4188-A994-894C25AF6816Q38161942-5820428A-E4D3-44DA-AC01-45CD281D2994Q38212471-D984D1DE-AC77-4709-B4AC-3C2E3FEF7C2C
P2860
Global levels of histone modifications predict prostate cancer recurrence.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Global levels of histone modifications predict prostate cancer recurrence.
@en
Global levels of histone modifications predict prostate cancer recurrence.
@nl
type
label
Global levels of histone modifications predict prostate cancer recurrence.
@en
Global levels of histone modifications predict prostate cancer recurrence.
@nl
prefLabel
Global levels of histone modifications predict prostate cancer recurrence.
@en
Global levels of histone modifications predict prostate cancer recurrence.
@nl
P2093
P356
P1433
P1476
Global levels of histone modifications predict prostate cancer recurrence
@en
P2093
Alexander von Ruecker
Bernhard Walter
Ferdinand Hofstädter
Ines Gütgemann
Johannes von der Gathen
Jörg Ellinger
Patrick J Bastian
Philip Kahl
Reinhard Büttner
Sebastian Rogenhofer
P356
10.1002/PROS.21038
P577
2010-01-01T00:00:00Z